BIOCRYST PHARMACEUTICALS INC (BCRX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, BIOCRYST PHARMACEUTICALS INC reported revenue of $874.84M, up 94.1% from the prior year. The company was profitable, with a net margin of 30.2%. It held $514.16M in total assets against $633.31M in total liabilities.
Key ratios (FY2025)
39.0%
Operating margin
30.2%
Net margin
+94.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $874.84M | $450.71M | $331.41M | $270.83M | $157.17M | $17.81M | $48.84M | $20.65M | $25.19M | $26.35M |
| Cost of Revenue | $19.07M | $12.27M | $4.48M | $6.41M | $7.23M | $1.55M | $3.73M | — | $1.14M | $2.30M |
| Operating Income | $340.99M | -$2.54M | -$103.71M | -$148.44M | -$177.72M | -$174.76M | -$99.45M | -$94.22M | -$57.41M | -$48.61M |
| Net Income | $263.86M | -$88.88M | -$226.54M | -$247.12M | -$184.06M | -$182.81M | -$108.90M | -$101.25M | -$65.78M | -$55.14M |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | — | — | — | — |
| Total Assets | $514.16M | $490.42M | $516.96M | $550.00M | $588.15M | $334.71M | $175.28M | $146.84M | $178.26M | $89.85M |
| Total Liabilities | $633.31M | $966.35M | $972.49M | — | — | — | — | — | — | — |
| Shareholders' Equity | -$119.15M | -$475.93M | -$455.53M | -$294.60M | -$106.99M | -$19.26M | $38.25M | $49.23M | $83.77M | $1.58M |
| Cash & Equivalents | $89.74M | $104.71M | $110.64M | $304.77M | $504.39M | $272.13M | $114.17M | $26.73M | $50.28M | $22.10M |
| Operating Cash Flow | $347.37M | -$52.02M | -$95.14M | -$161.85M | -$142.16M | -$135.11M | -$89.58M | -$92.56M | -$41.14M | -$53.44M |
| Capital Expenditures | $2.47M | $1.12M | $2.17M | $1.35M | $2.38M | $514.0K | $343.0K | $366.0K | $328.0K | $5.28M |
| Shares Outstanding | 213.06M | 208.54M | 205.77M | 187.91M | 184.35M | 176.88M | 154.08M | 110.06M | 98.41M | 73.78M |